Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT00230633

Studies of White Blood Cells Derived From HHT Patients

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Imperial College London · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels. The study goal is to culture white blood cells that express the proteins mutated in HHT and examine in the laboratory to explain aspects of the HHT disease phenotype.

Detailed description

HHT is a vascular condition but many of the genes that are mutated to cause HHT (endoglin, ALK-1 and SMAD4) are also expressed in white blood cells. In this study, investigators will take blood samples from people with HHT, culture the white blood cells and study their properties in media prompting different types of differentiation, or infection of cell lines with Epstein Barr virus to provide cell lines which can be repeatedly studied. RNA and proteins will be extracted from these cells for study of white cell responses and association with expression levels of endoglin, ALK-1 and SMAD4. The investigators hypothesize that these cells which express "half-normal" endoglin, ALK-1 or SMAD4 will show differences when compared to normal white blood cells. It is also anticipated that that these findings may help to explain aspects of the HHT disease phenotype.

Conditions

Timeline

Start date
2002-04-01
Primary completion
2026-10-01
Completion
2026-10-01
First posted
2005-10-03
Last updated
2023-09-28

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT00230633. Inclusion in this directory is not an endorsement.